PMID- 21537476
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1949-8454 (Electronic)
IS  - 1949-8454 (Print)
IS  - 1949-8454 (Linking)
VI  - 1
IP  - 7
DP  - 2010 Jul 26
TI  - Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
PG  - 209-20
LID - 10.4331/wjbc.v1.i7.209 [doi]
AB  - Ovarian cancer is the leading cause of death in women with gynecological cancer. 
      Most patients are diagnosed at an advanced stage and have a poor prognosis. 
      Currently, surgical tumor debulking, followed by platinum- and taxane-based 
      chemotherapy is the standard treatment for advanced ovarian cancer. However, 
      these patients are at great risk of recurrence and emerging drug resistance. 
      Therefore, novel treatment strategies are required to improve outcomes for women 
      with advanced ovarian cancer. A variety of molecular targeted agents, the 
      majority of which are monoclonal antibodies and small-molecule protein-kinase 
      inhibitors, have been explored in the management of ovarian cancer. The targets 
      of these agents include angiogenesis, the human epidermal growth factor receptor 
      family, ubiquitin-proteasome pathway, epigenetic modulators, poly(ADP-ribose) 
      polymerase (PARP), and mammalian target of rapamycin (mTOR) signaling pathway, 
      which are aberrant in tumor tissue. The antiangiogenic agent, bevacizumab, has 
      been reported as the most effective targeted agent and should be included in the 
      standard chemotherapeutic regimen for advanced ovarian cancer. PARP inhibitors, 
      which are mainly used in breast and ovarian cancer susceptibility gene-mutated 
      patients, and mTOR inhibitors are also attractive treatment strategies, either 
      alone or combination with chemotherapy, for ovarian cancer. Understanding the 
      tumor molecular biology and identification of predictive biomarkers are essential 
      steps for selection of the best treatment strategies. This article reviews the 
      molecular mechanisms of the most promising targeted agents that are under early 
      phase clinical evaluation for ovarian cancer.
FAU - Itamochi, Hiroaki
AU  - Itamochi H
AD  - Hiroaki Itamochi, Department of Obstetrics and Gynecology, Tottori University 
      School of Medicine, 36-1 Nishicho, Yonago 683-8504, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Biol Chem
JT  - World journal of biological chemistry
JID - 101546471
PMC - PMC3083967
OTO - NOTNLM
OT  - Epithelial ovarian cancer
OT  - Molecular target
OT  - Monoclonal antibody
OT  - Small-molecule inhibitor
OT  - Targeted therapy
EDAT- 2011/05/04 06:00
MHDA- 2011/05/04 06:01
PMCR- 2010/07/26
CRDT- 2011/05/04 06:00
PHST- 2010/06/01 00:00 [received]
PHST- 2010/07/08 00:00 [revised]
PHST- 2010/07/15 00:00 [accepted]
PHST- 2011/05/04 06:00 [entrez]
PHST- 2011/05/04 06:00 [pubmed]
PHST- 2011/05/04 06:01 [medline]
PHST- 2010/07/26 00:00 [pmc-release]
AID - 10.4331/wjbc.v1.i7.209 [doi]
PST - ppublish
SO  - World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209.